News
11-21-2010, 11:21 PM
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
More... (http://www.news-medical.net/news/20101122/Phase-3-study-of-VEGF-Trap-Eye-regimen-meets-primary-endpoint-in-patients-with-wet-AMD.aspx)
More... (http://www.news-medical.net/news/20101122/Phase-3-study-of-VEGF-Trap-Eye-regimen-meets-primary-endpoint-in-patients-with-wet-AMD.aspx)